Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin ; day:29 ; month:4 ; year:2022 ; pages:1-13
Heart failure reviews ; (29.4.2022), 1-13

Urheber
Aimo, Alberto
Senni, Michele
Barison, Andrea
Panichella, Giorgia
Passino, Claudio
Bayes-Genis, Antoni
Emdin, Michele
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10741-022-10228-8
URN
urn:nbn:de:101:1-2022071010313130497377
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:20 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Aimo, Alberto
  • Senni, Michele
  • Barison, Andrea
  • Panichella, Giorgia
  • Passino, Claudio
  • Bayes-Genis, Antoni
  • Emdin, Michele
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Biomarkers in heart failure with preserved ejection fraction

Biomarkers in heart failure with preserved ejection fraction

Comorbidities in heart failure with preserved ejection fraction

Comorbidities in heart failure with preserved ejection fraction

Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis

Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis

Animal models of heart failure with preserved ejection fraction

Animal models of heart failure with preserved ejection fraction

Heart Failure with Preserved Ejection Fraction—a Concise Review

Heart Failure with Preserved Ejection Fraction—a Concise Review

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction

133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction

Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure

Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure

Gender-related differences in heart failure with preserved ejection fraction

Gender-related differences in heart failure with preserved ejection fraction

Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction

Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction

Verbundene Objekte